Table 6. Hematological indexes and tumor markers before and at 1 month after 125I seed implantation.
| Clinical symptoms | Before 125I seed implantation (assessed n=15) | One month after 125I seed implantation (assessed n=15) | P |
|---|---|---|---|
| WBC (×109/L) | 5.5 (4.4–7.3) | 6.7 (5.5–9.1) | 0.085 |
| RBC (×1012/L) | 3.7 (3.3–4.2) | 3.6 (3.4–4.0) | 0.859 |
| ANC (%) | 66.6 (57.9–73.2) | 72.2 (61.8–79.6) | 0.086 |
| Hb (g/L) | 111.5 (104.5–127.5) | 113.5 (105.8–123.8) | 0.859 |
| PLT (×109/L) | 225.0 (123.0–266.5) | 221.5 (130.8–245.0) | 0.139 |
| CEA (ng/mL) | 2.9 (1.8–4.0) | 8.6 (2.0–285.1) | 0.593 |
| CA125 (U/mL) | 19.8 (10.7–67.0) | 67.9 (16.8–119.7) | 1.000 |
| NSE (U/mL) | 16.7 (15.3–20.8) | 19.2 (15.4–21.5) | 0.785 |
| SCCAg (ng/mL) | 1.4 (0.9–4.9) | 1.1 (0.5–12.7) | 0.465 |
| Cyfra21-1 (ng/mL) | 5.2 (2.9–9.5) | 7.9 (2.5–13.2) | 1.000 |
Data were presented as median (25th–75th quantiles). Comparisons were determined by Wilcoxon signed rank test. P<0.05 was considered significant. 125I, iodine-125; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet; CEA, carcinoembryonic antigen; CA125, Carbohydrate antigen 125; NSE, 2-phospho-D-glycerate hydrolase; SCCAg, squamous cell carcinoma antigen; Cyfra21-1, cytokeratin 19 fragment.